Official opening of new facilities for ground breaking molecular diagnostics company
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Raman Spectroscopy (SERS) and Surface Enhanced Resonance Raman Scattering (SERRS) for clinical research and molecular diagnostics applications, today held its official opening of expanded premises on the Nova Technology Park. [17 kB] Ground breaking molecular diagnostics business appoints new CEO
Glasgow, Scotland, 3rd February 2010: D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface-Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance Raman Scattering (SERRS), today announced that it has appointed David Burns as its new Chief Executive Officer. He will lead the Company towards the international launch of its first in-vitro diagnostic (IVD) products, with the aim to establish D3 Technologies as a global play [16 kB] D3 Technologies Ltd is now Renishaw Diagnostics Ltd
Glasgow, Scotland, 11th May 2010: D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Resonance Raman Scattering (SERRS) for molecular diagnostics and research applications, today announced that it has changed its name to Renishaw Diagnostics Ltd. [14 kB] Renishaw Diagnostics defies the job loss trend
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced resonance Raman scattering (SERRS), for life science research and molecular diagnostics applications, today announced its intention to create another 7 new jobs immediately: almost a 30% increase on its current workforce. [14 kB] Renishaw Diagnostics Gains ISO 13485 Certification
Renishaw Diagnostics Ltd, developers of the RenDx™ Multiplex Assay System for infectious disease research and diagnosis, today announced that it has been certified to ISO 13485:2003 for the following scope: design, development, product manufacture and management of subcontracted manufacture of molecular diagnostic systems for infectious diseases. [14 kB] Renishaw Diagnostics enables customised multiplex assays for precious research samples
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced the launch of its first research use only (RUO) multiplex assay system which allows precious research samples to be ‘screened’ for 10 or more ‘targets’, from a single sample. [16 kB] Renishaw invests in D3 Technologies Limited
Renishaw is pleased to announce it has acquired a 75% interest in D3 Technologies Limited (¢D3¢), a company set up in collaboration with the University of Strathclyde and others to exploit certain patents related to Surface Enhanced Raman Spectroscopy (¢SERS¢) and to develop SERS for molecular diagnostics and trace detection. [13 kB] D3 Technologies Ltd nominated for Life Sciences Award
Glasgow based company, D3 Technologies Ltd, a subsidiary of Renishaw plc, has been shortlisted for a prestigious Scottish Enterprise Life Sciences Award 2009. The nomination for the Most Promising New Life Science Company in Scotland recognises the work of D3 Technologies in the area of molecular diagnostics. [14 kB] Renishaw Diagnostics signs exclusive licence agreement for SERRS Beacons with The University of Strathclyde
Renishaw Diagnostics Ltd, today announced that it has concluded an exclusive licence agreement to a patent on nucleic acid sequence identification (SERRS beacons) from The University of Strathclyde.David Burns, CEO said “We are very pleased to have secured this licence for such an important piece of intellectual property. Although we have just launched our first major product, the RenDx™ Multiplex Analysis System for research use only in infectious diseases, we are already looking to devel [17 kB] Renishaw: enhancing efficiency in manufacturing and healthcare
In metrology, motion control, machine calibration, dental CAD/CAM, additive manufacturing, spectroscopy and neurosurgery, Renishaw innovations enhance precision, efficiency and quality. Products include CMM touch-trigger probes, scanning probes, CMM retrofits, gauging, machine tool touch probes, laser probes, linear encoders, angle encoders, magnetic encoders, magnetic rotary encoders, Raman spectroscopy, laser calibration, selective laser sintering, dental scanners and neurosurgical robots. [21 kB] D3 Technologies provides R&D to aid chronic wound care
Renishaw subsidiary D3 Technologies Ltd has been confirmed as an R&D provider to ITI Techmedia 's research and development Programme that will develop technology to aid healthcare clinicians with wound infection diagnosis and the management of chronic wounds. The technology is set to enable wound care therapies that will significantly improve patients’ quality of life and reduce associated healthcare costs. [21 kB] Research and development
Group Engineering provides software, electronics, design testing, rapid prototyping and research services, supporting innovation throughout the Renishaw Group. [14 kB]
Ground breaking molecular diagnostics business appoints new CEO
D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface-Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance Raman Scattering (SERRS), today announced that it has appointed David Burns as its new Chief Executive Officer. He will lead the Compan [143 kB] New CEO required for ground breaking molecular diagnostics business
(3rd June 2009): D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Raman Spectroscopy (SERS) and surface enhanced resonance Raman scattering (SERRS), today announced that it has initiated a search for a new Chief Executive Officer. The Comp [146 kB] D3 Technologies Ltd is now Renishaw Diagnostics Ltd
D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Resonance Raman Scattering (SERRS) for molecular diagnostics and research applications, today announced that it has changed its name to Renishaw Diagnostics Ltd. [172 kB] Renishaw invests in D3 Technologies Limited
Renishaw is pleased to announce it has acquired a 75% interest in D3 Technologies Limited ("D3"), a company set up in collaboration with the University of Strathclyde and others to exploit certain patents related to Surface Enhanced Raman Spectroscopy ("SERS") and to develop SERS for molecular diagnostics and trace det [21 kB] D3 Technologies Ltd nominated for Life Sciences Award
Glasgow based company, D3 Technologies Ltd, a subsidiary of Renishaw plc, has been shortlisted for a prestigious Scottish Enterprise Life Sciences Award 2009. The nomination for the Most Promising New Life Science Company in Scotland recognises the work of D3 Technologies in the area of molecular diagnostics. [135 kB] Renishaw Diagnostics CEO appointed to Scottish Life Sciences Advisory Board
David Burns, CEO of Glasgow-based Renishaw Diagnostics Ltd, has been appointed to the Life Sciences Advisory Board (LiSAB) for Scotland.LiSAB is a joint industry, enterprise and government strategy team which develops and drives the overall life sciences strategy in Scotland. It consists of representatives from across [168 kB]
Certificate of registration ISO 13485 bannerRenishaw Diagnostics Ltd, today announced that it has been certified to ISO 13485:2003 for the following scope: design, development, product manufacture and management of subcontracted manufacture of molecular diagnostic systems for infectious diseases. - [760 x 220 pixels] [91 kB]
- [50 x 50 pixels] [5 kB]
|
|